are all probably related to the different stages of B-cell maturation and function, and their inclusion in a "receptor profile" of lymphoma is important. Secondly, the dominant cell populations in various normal and reactive lymphoid tissues were analysed with these markers. Thirdly, the characteristics of neoplastic populations from 157 cases of non-Hodgkin lymphoma were established, and correlated with the histopathological and cytological features of these tumours. The sequential analysis of serial samples from some of these patients suggested certain developmental links between the different subclasses of lymphoma and their normal equivalent B-cell subtypes.
MATERIALS AND METHODS
Tissues from 157 patients with nonHodgkin lymphoma were studied. These included 44 patients with CLL whose blood was studied. Single-cell suspensions were prepared from various lymphoid organs. Blood, marrow and spleen suspensions were separated on Ficoll-Triosil, and surface marking performed on the recovered white-cell layers. Touch preparations were made from the cut lymph node surface and cytocentrifuge preparations from cell suspensions. These were studied by cytology and cytochemistry. Trephine biopsy samples of marrow and paraffin-embedded preparations were studied by histology. Histological and cytological diagnoses were made independently of knowledge of the receptor profile. The determination of the receptor profile of single-cell suspensions was carried out as follows.
Preparation of rosettes E rosettes.-106 washed leucocytes were mixed with 40 x 106 washed sheep RBC in 500 dul of Medium 199, incubated for 10 min at 37°C, centrifuged for 5 min at 100 g, and incubated in the pellet for 2 h at 4C. After gentle resuspension, 5 pkl of 041% solution of acridine orange was added, and the preparation examined wet using a microscope with a tungsten-halogen light source and dichroic filtered (narrow-band blue/red) light. The stained nuclei fluoresce green, enabling the easy identification of rosetting cells. Nucleated intact cells binding more than 3 red cells were counted as rosettes.
Fc rosettes.-Rabbit anti-ox-RBC IgG was prepared from hyperimmune rabbit serum by (NH4)2SO4 precipitation and DEAE-cellulose chromatography. Optimal titre for red-cell sensitization was determined as that titre giving the maximum level of Fc rosetting by normal blood mononuclear cells without agglutination. The numbers of rosettes formed with increasing amounts of antibody on the red cells shows a plateau at 20-35% rosettes with samples of normal blood mononuclear cells.
IgM rosettes.-Rabbit anti-ox-RBC IgM was prepared by the i.v. injection of rabbits with 2-5 mg/ml (wet wt) of ox erythrocyte stroma suspended in 5% gelatin solution (Kabat & Mayer, 1961) . The first peak on G-200 Sephadex chromatography (1gM) was separated. IgM titres for red cell sensitization (IgM rosettes) were selected by titration of antibody dose against percentage rosettes using IgM+ CLL cells. Kinetics of IgM rosetting were similar to Fc rosetting, although IgM rosettes are not formed in the presence of free human IgM. Red cells sensitized for 30 min at 37WC were used to prepare rosettes by the same method as for E rosettes.
C3d rosettes.-Ox RBC were coated with a titre of rabbit-anti-ox-RBC IgM antibody found to give optimal complement binding. Sensitized cells were then treated with human R3 reagent (Lachmann et al., 1973) and washed twice. The receptor expressed is the C3d receptor, since such cells react with anti-human C3 antisera but are immune-adherence-negative. Rosetting was performed as for E rosettes. 
RESULTS-II
Peripheral blood in CLL (Table II) In all but 2 of the 44 cases examined, monoclonal SIg could be detected after acetate washing and incubation of the cells. In 2 cases, removal of polyclonal SIg was followed by failure to detect any SIg on the cells. In all samples studied, T cells formed less than 10% of the circulating population. SIg expression was invariably weak, and single-chain only (most commonly ,u or K) in 26 cases. The surface phenotype of the cases of CLL seen is given in Table II (2) and Lov. (1, 2, 3) had repeat biopsies. Two patients had T-cell-predominant tumours (Ham., Lov.). Lov. had a T-cellpredominant tumour which became E-in a subsequent biopsy (not tested with anti-HTLA). Ham. had an immunoblastic lymphoma of T-cell type. One patient (Tun.) had a true receptor-silent tumour (E-SIg-ALL-HTLA-). Two patients (Byi., Fin.) were judged to have malignant histiocytosis on cytology and cytochemistry. In both biopsy specimens large numbers of functional phagocytes were present. In Patient Fin. these cells were accompanied by a B-cell population expressing K chain only. Large receptor- silent cell populations were also present in these cases.
Comparing the Kiel classification with the surface markers in this group, the diagnosis of "immunoblastic malignant lymphoma" (ML IB) corresponded closely with B-cell predominant tumours, the exception being patient Tun. who had a receptor-silent neoplasm. In 2 patients, Smi. (2), Hug., the diagnosis indicated immunoblastic transformation in a centroblastic and centrocytic tumour. Both Tcell-predominant monoclonal B -cell tumours were diagnosed as "malignant lymphoma centroblastic" in the Kiel classification. The cases of T-cell malignancy were classified as a "centrocytic tumour of large cell type", and as ML IB.
The evidence from this series shows that the majority of DH lymphomas are of B-cell derivation, and are composed of large cells which are slow to cap SIg antiimmunoglobulin complex. T-cell lymphomas are rare in this histological class. DH lymphomas which lack surface Ig, Fc, C3d and E receptors may contain CyIg, or may be receptor silent. True histiocytic malignancies are rare. Surface phenotype in diffuse poorly differentiated lymphocytic lymphoma (DPDL) ( Table V) Twenty-four patients in this group contributed 27 biopsy specimens of involved tissue. In all but 4 patients the lesion examined was B-cell predominant. In the remaining 4 biopsy specimens, 2 showed T-cell predominance with monoclonal B cells, and 2 T-cell predominance with polyclonal B cells. No receptor-silent tumours occurred in this group. Four patients had non-capping B-cell tumours, all classified as centrocytic tumours of large or pleomorphic cell type (Kiel). Three patients had non-capping tumours expressing C3d receptor, all classified as centrocytic tumours of small cell type (Kiel). Nine patients had capping tumours expressing C3d receptors, and one of these (Mat.) showed monoclonal IgG in the cytoplasm of 10% of the tumour cells.
Six biopsy specimens showed a B-cellpredominant pattern with the phenotype SJg+, and 2 of these were polyclonal. Five patients had low-grade tumours which could not be definitively assigned to any single class in the Kiel classification, although the phenotype in two of these cases (Wil., Mat.) was that of the follicular tumour (SIg+ C3d+: Kiel equivalent centroblastic/centrocytic/diffuse).
Surface phenotype in nodular poorly differentiated lymphocytic lymphoma (NPDL) ( Table VI) Thirty-two patients in this class provided 47 profiles. The majority of patients (27/32) presented with tumours in which B cells were the predominant population, or with T-cell-predominant tumours containing monoclonal B cells. Non-capping B-cell tumours presented in 5 patients. In Gig. (3) the tumour cells capped slowly, rather than failing to cap at all. In 12 patients, the first lesion in the series showed a predominant population of B cells with S1g+C3d+ phenotype. This was the most frequent profile in tumours of this class. Seven patients had lesions in which capping SIg+ cells were the major population. Four patients had T-cellpredominant lesions on presentation, and these patients all eventually showed B-cell monoclonality, in contrast to some of the T-cell-predominant tumours of DPDL, DH, or DU classes. No true nodular T-cell tumour has been seen in this series. Two tumours (Ayl. (1), Tay) showed the unusual profile of SIg+Fc+C3+ B-cell predominance, and 2 tumours were receptor-silent (Eve., Spe.). Only one of the nodular tumours (Ted. (3a)) showed CyIg in more than 10% of cells. Correlating phenotype with histological classification, most of the lesions expressing only surface immunoglobulin (SIg+ capping) showed sclerosis of the node on histological examination. All the lesions classified as "nodular poorly differentiated", or as "nodular mixed", were classified as "centroblastic centrocytic follicu- The node profile suggested a T-cell neoplasm, but cytologically the predominant cell type was immunoblastic. The disease progressed to involve marrow and blood. The immunoblastic cytology persisted with E+ cell markers. This is the second case of T-cell immunoblastic tumour in this series (see patient Ham., DH). Variations in profile and histology on repeat biopsy Changes in the histology of lymphomas during the course of the disease frequently involve conversion of a nodular lymphoma into diffuse lymphocytic or histiocytic lymphoma. In an attempt to document these changes, repeat biopsy specimens were examined in 23 patients. In patients Dep. (1, 2) , Bro. (1, 2) and Tue. (2, 3) lymphnode and spleen profiles were assessed concurrently, where laparotomy provided samples of involved spleen and node on the same day. These are not included in this section but are given in the appropriate Tables. In 2 of these patients the profile of tumour from node and spleen was the same (Dep. (1, 2), Bro. (1, 2)) while in Tuc. (2, 3) the node profile showed SIg+C3+ cells and the spleen profile SIg+Fc+C3+IgM+ cells.
In the remaining 21 patients, the histological variation and the change in surface profile, together with the interval between biopsies is given in Table IX . Four types of change occurred:
(1) Changes in histological appearance.
Nine patients (Mad., Smi., Has., Koz., Ted., Bri., Ayl., Cha., Cou.) showed changes. In Mad., the change was from a high-grade pleomorphic tumour into a malignant lymphoblastic lymphoma. This change was associated with loss of E+ by the cells in this T-cell tumour, with reversion to an E HTLA+ phenotype. In patient Smi., the change from a malignant lymphoma of centroblastic type into a tumour containing both centroblasts and immunoblasts was accompanied by a change in profile from T predominance with monoclonal B cells into a noncapping lymphoma. In patient Has., the histological pattern changed from CB/ cc/F (NPDL) to an immunoblastic malignant lymphoma (DH) accompanied by a change in phenotype from SIg+C3+ to a non-capping B-cell tumour. In patient Koz., 3 biopsy specimens showed marked histological progression from a lymphoplasmacytoid tumour to an unclassified low-grade malignant lymphoma to an immunoblastic lymphoma (DH). The profile altered during this sequence from SIg+C3+ to T-cell-predominant monoclonal B, and terminated in a non-capping B cell tumour. Patient Ted. underwent 4 biopsies (1, 2, 3, 3a) . Nodes 3 and 3a were removed at one operation, 3 from the inguinal region, 3a from the axilla. All showed evidence of nodularity, but in contrast to biopsy specimen 1, biopsy specimens 2 and 3 showed some blast transformation with evidence of progression to a diffuse tumour (from CB/cc/F to CB/D). Biopsy specimen 3a showed preservation of the follicular appearance of biopsy specimen 1 (CB/cc/F). The phenotype of the node cells showed changes in the numbers of non-capping cells, and in T cells associated with these histological changes (Table VI) . In patient Bri., the histology altered from a nodular and diffuse poorly differentiated tumour to a diffuse mixed lymphocytic and histiocytic lymphoma accompanied by a change in profile from SIg+C3+ to SIg+. In both biopsy specimens SIg expression was polyclonal. In patient Ayl., the histological change was from nodular mixed lymphocytic and histiocytic lymphoma to a nodular poorly differentiated tumour with sclerosis. This was accompanied by a change in profile from SIg+Fc+C3+ to SIg+C3+. In patient Cha., an alteration from a purely nodular tumour (NPDL; CB/cc/F) to a mixed nodular and diffuse tumour (N+DPDL, CB/cc/F+D) was not accompanied by any change in profile. In patient Cou., a nodular mixed lymphocytic and histiocytic tumour (CB/cc/F) progressed to a nodular and diffuse poorly differentiated lymphoma (CB/cc/F+D). This was accompanied by a change in profile from T-cell predominance to T-cell predominance with monoclonal B cells.
(2) Changes in surface markers with no histological change.-Patients Lov. (1, 2, 3), Eva. (1, 2), Gig. (1, 2, 3 Ted., the initial biopsy specimen was ILA monoclonal, the last (3a) showed pA SIg with some yA CyIg+ cells. In Eva., the heavy-chain class altered from y to ,u in a K chain-expressing tumour between the first and second biopsies. In Cou., no SIg+ cells occurred in the first biopsy specimen, but >10% of cells in the second biopsy specimen were B cells and were FK monoclonal. In patient Gig., a B-cell component became predominant between the first and second biopsies and there was a change from polyclonal SIg expression to y,A expression. Between the second and third biopsies, IL expression was lost, giving a yA monoclonal B-cell tumour. In Patient Tuc., the first biopsy specimen showed only H heavy chain on the B cells; the second biopsy showed VK monoclonality. In Patient Wil. (2, 3) a yK monoclonal SIg profile in the second biopsy specimen had become polyclonal by the time of the third biopsy. In Patient Hai., a polyclonal Bcell component seen at the first biopsy expanded to a monoclonal B-cell component by the second biopsy, expressing PK Slg.
(4) No change in histology or profile.-Patients Bre., Bret., Pet., Sul., did not show changes either in histology or profile between the first and second biopsies. If allowance is made for the fact that the second biopsy in Bre. was done on cells from a malignant effusion, the profiles obtained (Table III) are probably equivalent, although in the node biopsy IgM receptor was present on a substantial proportion of T cells, and C3 was less well represented than in the pleural effusion. It is of interest that the SJg expression in both Bret. and Sul. remained polyclonal in both biopsy specimens, and no alteration in histology or profile was seen.
In Patients Pea. and Cal., changes in histology and profile are not comparable with those described in the other patients. In Patient Pea. the original biopsy specimen was not diagnosed as lymphoma. Only later, with the appearance of many circulating immunoblasts, was the progressive nature of the tumour appreciated. Profiles on blood, in our experience, are rarely interpretable in the same way as node or spleen profiles, and are probably the least representative of the involved tissues in non-Hodgkin lymphoma. In Patient Col., it is possible that 2 separate proliferating populations were initially present: B cells in lymphnode and T cells in marrow.
Expression of SIg class in non-Hodgkin lymphomas of different histological type (Table X) The majority of neoplasms express ,u heavy chain as the major immunoglobulin heavy-chain class. y Heavy chain is expressed with similar frequency in DU, DH, and DPDL lymphomas, but is rarely expressed in NPDL or DWDL lymphomas. Single-chain expression is unusual in DU, DH, DPDL or NPDL, but is very common in DWDL. In DHL, DU and DWDL, K light chain is expressed more frequently than A; in DPDL A chain is expressed more frequently than K. In NPDL the K/A ratio is of the same order as in normal lymphnode cell suspensions. The number of B-cell-predominant polyclonal SIg+ tumours is greater in NPDL lymphoma than in the other classes. Of the many available classifications of non-Hodgkin lymphoma we chose to base this paper on two, the Rappaport scheme because of its proven clinical applicability, and the Kiel because it is one of the two major classifications embodying the Lukes and Collins follicular-centre-cell concept (Lukes & Collins, 1975; Gerard-Marchant et al., 1974) . Both classifications have strong and weak points: the Rappaport is simple to understand, and easy to apply. The major defect in the scheme lies in the mistaken concept of lymphocyte "differentiation" and in the division between histiocytic lymphomas (which are mainly lymphocytic) and lymphocytic lymphomas (Habeshaw et al., 1977) . The Kiel classification avoids these drawbacks, but is of a higher order of complexity and is largely unproven "in the field" of clinical applicability. In the first part of this discussion an attempt will be made to assess the validity of certain Kiel concepts, namely the ability to distinguish between B-and T-cell lineages cytologically, to identify follicular-centre-cell lesions, and to explore the Kiel division of the Rappaport "DWDL" lymphoma, into lymphocytic and lymphoplasmacytoid subgroups.
In the Kiel classification, lymphoblasts of B and T type are distinguished from those of ALL+ type by cytology (convoluted nucleus, acid-phosphatase-positive T, cytoplasmic vacuolation and basophilia B). As shown in Table III , in 7 cases of T-lymphoblastic lymphoma proven by phenotype, 5 showed the cytological features of T lymphoblasts. Patients Leg. and Mad. did not show these features, and in both cases the lymphoblasts were E-and HTLA+. These two cases may represent tumours of prethymic T lymphocytes (Kersey et al., 1974) . Of the 5 B-lymphoblastic lymphomas, 3 showed Burkitt-lymphoma-like features. Of interest is the presence of cytoplasmic immunoglobulin in 2 of these tumours, suggesting a relationship with the pre-B cell (SIg-CyIgM+ phenotype).
The Kiel classification stresses the interrelationship between centrocytes of largeand small-cell type, centroblasts, and immunoblasts as successive stages in the maturation of follicular lymphocytes to plasma cells. Lukes proposes a similar but not identical maturation sequence of small cleaved cell, large cleaved cell, small noncleaved cell and large non-cleaved cell to the B-cell immunoblast. In terms of surface phenotype, normal follicular tissues show the presence of centrocytes of small-and large-cell type, which exhibit the SIg+C3d+ phenotype. Associated with these B cells are normally found a significant proportion of small and transformed cells (not centrocytes) which express Erosetting capabilities, and are HTLA+. In the tumours examined, most tumours containing SIg+C3d+ B cells had centroblastic and centrocytic morphology. However, of the 52 cases of centroblastic and centrocytic type, only 24 showed SIg+C3d+ phenotype. In 26 of these 52 cases, centroblastic and centrocytic tumours contained more than 20% of T lymphocytes, and some were T-lymphocyte-predominant. While there remains a good correlation between monoclonal B-cell-predominant tumours and the histological class "centroblastic and centrocytic" lymphoma, it is apparent that the B-cell subtype SIg+C3d+ is not detected in these tumours by morphology and cytology. The centroblastic component of the centroblastic and centrocytic tumour may well be T-rather than B-derived on the evidence of this series, because (1) 60% of purely centroblastic tumours were T-cell predominant; (2) centrocytic tumours of small-and large-cell type were B lymphoid; and (3) of the high incidence with a T-cell population >20% in tumours with a centroblastic component. If the "centroblast" is T-lymphoid, the relationship between the 2 centrocytic components and the immunoblast becomes easier to understand. The small-cell centrocytic tumours are frequently SIg+C3d+; some fail to cap SIg. The large-cell centrocytic tumours appear to lack C3d receptors, and are phenotypically similar to the B immunoblast (non-capping SIg+). Small -cell centrocytic tumours and some centroblastic and centrocytic tumours have the phenotype SIg+, which is also common in lymphoplasmacytoid malignancies. The latter can express SIg+C3d+, and SIg+Fc+ C3d+ phenotypes in addition. Our interpretation of the interrelationships of follicular lymphocyte subtypes in the Kiel classification would favour: (1) centroblast, and the non-transformed "small non-cleaved cell" of Lukes are T cells and represent the T-cell component associated with follicular B cells; (2) the small centrocyte (SIg+C3d+) transforming to the large centrocyte (SIg+, non-capping) and to the immunoblast (non-capping SIg+) or remaining untransformed, giving rise to the "lymphoplasmacytoid" lymphocyte (SIg+, SIg+Fc+C3d+ In respect of the recognition of the classes of follicular-centre-cell derived tumours, the categorization morphologically and cytologically of T-and Blymphoblastic tumours, and the distinction between the lymphoplasmacytoid and lymphocytic forms of diffuse lymphoma, the Kiel classification offers distinct advantages over the Rappaport scheme. The current limitations of histological and 29 cytological classification using either Kiel or Rappaport are also apparent when the phenotypic correlations are taken into account. Neither scheme recognizes subtypes of B cell clearly defined by phenotype. Neither scheme achieves a one-forone correlation of phenotype and morphology, even in a cytologically distinctive, monomorphic population. The conclusion clearly is that subsequent classifications of non-Hodgkin lymphoma must include surface marking as one of the diagnostic criteria.
When the correlations between surface marking and histology in the series of repeat biopsy specimens is examined, relationships between surface markers and histology become difficult to interpret. There is clear evidence of a relationship between T-cell-predominant monoclonal B-cell tumours, tumours of S1g+C3+ class and non-capping B-cell tumours of immunoblastic type. These sequences support the contention that tumours of follicular derivation are related to immunoblastic tumours. In terms of surface markers, there is strong evidence for believing that T-predominant monoclonal B-cell tumours and S1g+C3+ tumours are also functionally related, the end stage being either an SIg+ non-capping or an SIg+ tumour. The occurrence of T-cell predominance as one phase in the development of an SIg+C3+ or non-capping SIg+ tumour has not previously been recognized. It is of importance, since in the normal immune response T cells accumulate in lymph nodes early, and their accumulation and division precede B-cell hyperplasia and antibody secretion (Davies et al., 1969) . Centroblastic tumours (although rare in this series) seem to correlate with the T-cell-predominant phase of what later becomes a B-cellpredominant tumour. Although the evidence is limited, we would like to suggest that the tumour of SIg+C3d+ phenotype is sandwiched between 2 T-cell-predominant phases, one of which precedes the expansion of the SIg+C3d+ clone, and the other which marks the transition between the SIg+C3d+ phenotype and the capping or non-capping SIg+ tumour. During the first phase, the emergence of a follicularcell pattern occurs, and during the second a change from a nodular to diffuse histological pattern is seen. Immunoglobulin switching from ,u to y class, and the synthesis of CyIg probably occur after the second phase of T-cell predominance.
2. Deductions about the nature of NHL from these studies Lymphomas are tumours of the immune system. The fact that they arise at all reflects some profound disturbance not just in the cell class termed "neoplastic" but in the precursors of that cell and in related cells which physiologically regulate the normal response to an antigen. A stemcell defect in this system may be latent in both B-and T-cell lines, without compromising the function of either, until they meet the appropriate antigenic stimulus. If the defect is expressed in immunologically competent cells, and concerns events which occur after exposure of the cell to antigen, it will only become apparent as a failure of that cell to complete the immune response which would normally follow such exposure. In this sense, nonHodgkin lymphoma (NHL) can be regarded as an abnormal immune response equivalent to a selective immune deficiency, limited to one clone of cells and evoked by a single antigen. Evidence for this statement is based on the close similarity between the chromosomal defect in ataxia telangiectasia and defects described in various forms of lymphoma (Louie & Schwartz, 1978; McCaw et al., 1975; Fukahara et al., 1976; Manolov & Manolova, 1972) and on the antibody activity of monoclonal immunoglobulins isolated from patients with lymphoma (Salmon & Seligmann, 1974) .
Lymphomas can be broadly divided into two groups: (1) occurring before full functional differentiation of the lymphoid cells has been achieved and (2) tumours of differentiated lymphocytes. In Group 1 the tumours are of immunologically incompetent cells, and are independent of any antigenic stimulation. In Group 2 the tumours are of immunologically competent cells which are maturation-arrested at some stage in their response to an antigen. The defect (or oncogenic event) may be present in either tumour from the stemcell stage, but in Group 1 tumours is expressed before the cell has achieved immunocompetence and in Group 2 tumours after functional differentiation is complete. Using this model it is possible to utilize the available evidence of normal differentiation to explore the nature of NHL.
Tumours of incompetent cells are the ALL+Ia+ lymphoblastic and the T-cell lymphoblastic lymphomas, including the E+C3+ subset. These tumours are usually TdT+ (Kung et al., 1978) . It is during this phase of development that B and T cells acquire their antigen receptors by a process of proliferation, somatic mutation and elimination of self-antigen-reactive clones (Jerne, 1971) . It has been suggested that TdT enzyme is important during the somatic mutation step in which the variable-region genes are assembled which code for the antigen-receptor sites on both the T-cell surface and the immunoglobulin molecule (Baltimore, 1974) . The tumours of immunologically incompetent B cells are represented only by the pre-B cell ALL, since a measure of immunocompetence is present from the exhibition of SIg. All SIg+ B-cell tumours are TdT- (Kung et al., 1978; Donlon et al., 1977; Habeshaw et al., submitted for publication) . Immature, but SIg+ B cells have some immunocompetence. Their maturation can be blocked at this stage by antiIgM antibody (Kearney et al., 1976) . After contact with anti-IgM, immature B cells shed their SIg and fail to secrete it again until the blocking agent is removed (Stocker, 1977; Sidman & Unanue, 1975) . The effects of "blocking" B cells are reminiscent of the effects of removing polyclonal antibody from CLL cells by acetate washing, where only a weak or residual SIg positivity is retained, or in 3 some cases no SIg expression at all. For this reason, the weakly staining CLL cells, and the malignant lymphomas of lymphocytic type may be tumours of immature B cells. It has been shown that Fe expression is an early characteristic of the B cell, preceding acquisition of the C3 receptor , and that SIg+Fc+ B cells require the presence of primed T cells and macrophages in order to respond to an antigen (Hoffman et al., 1976) . Virgin B cells, with SIg+Fc+C3+ (and possibly IgM+) phenotype, can respond to antigen in the presence of unprimed T cells and macrophages (Kearney et al., 1978) . The presence of weak SIg expression and SIg+Fc+(IgM+) phenotype as in CLL, might suggest tumours of immunocompetent but immature B cells. The profile of the virgin B cell is perhaps SIg+Fc+C3+IgM+, with surface IgM or IgM+D as the major SIg class (Coffman & Cohn, 1977) . Most NHL are composed of B cells derived from the later phases of B-cell maturation. During germinalcentre development expansion and selection of antigen-reactive clones derived from marrow precursors occurs . The products of such selection are plasma-cell precursors and memory cells which, though derived from the same clone, probably belong to different maturation compartments (Zauderer & Askonas, 1976) . Tumours of germinal-centre cells are represented by those of SIg+C3+ profile. Memory-cell tumours are of unknown profile, but since normal memory cells circulate and accumulate in the spleen their tumours may have SIg+Fc+C3+ phenotype. According to one view ) the SIg+C3+ precursor from marrow has SIg+C3-phenotype. T-cell help may be required for the differentiation of the SIg+C3+ B cell into a plasma-cell precursor (Lewis et al., 1976) . Pro-plasma cells do not recirculate and they probably express SIg+ or SIg+CyIg+ profiles.
It is possible to identify those critical 31 points in normal lymphocyte development at which tumours arise. These are (1) at stem-cell stage (ALL+la+TdT+) or early in the differentiation sequence (pre-B, pre-thymic and thymic T cell); (2) between acquisition of SIg and virgin B-cell stage (as in MLL and CLL); (3) during germinal-centre formation (SJg+ C3+ tumours) in which there is at least one T-cell-predominant phase; or (4) during the change from SIg+ to Cylg+ cell, which may also include a T-cell-predominant phase and be accompanied by IgM-G switching and blast-cell transformation. The question how these maturation arrests occur should provide a useful challenge to the continuing investigation of non-Hodgkin lymphoma.
